FDA Drops New Guides for Faster Generic Drug Approvals
Published Date: 10/2/2025
Notice
Summary
The FDA just released new draft guides to help drug makers design studies proving their products work like the originals. These guides affect companies making generic drugs and aim to speed up approvals while saving money. Check them out soon to stay ahead and keep your products on track!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Draft Bioequivalence Guides for ANDA Sponsors
The FDA released new draft and revised draft product-specific guidances that give recommendations on designing bioequivalence (BE) studies to support Abbreviated New Drug Applications (ANDAs). If you make generic drugs or submit ANDAs, these guidances tell you FDA's recommended study designs and were developed using the process the FDA described on June 11, 2010.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-19344, Future of the HECM and HMBS Programs and Opportunities for Innovation in Accessing Home Equity
HUD wants to hear from senior homeowners and others about how to make reverse mortgages better and easier to use. These changes could help seniors tap into their home’s value more smoothly and keep the programs strong for the future. If you’re a senior or work with home loans, your ideas could shape updates coming soon that might affect money and timing.
Next: 2025-19347, Notice of OFAC Sanctions Actions
The U.S. Treasury’s OFAC just added new people to its blacklist, meaning their money and property in the U.S. are frozen. Americans can’t do business with these folks anymore. This move helps keep bad actors out of the U.S. financial system, effective immediately.